Overexpression of High-Mobility Motor Box 1 in the Blood and Tissues of Patients with Head and Neck Squamous Cell Carcinoma

Document Type: Original


1 Dental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Department of Otorhinolaryngology, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Department of Biostatic, Mashhad University of Medical Sciences, Mashhad, Iran.


Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in the world. Extra- and intra-cellular high-mobility motor box 1 (HMGB1) proteins are invovled in the pathogenesis and prognosis of cancer. Regarding this, the present study was conducted with the aim of investigating the expression of HMGB1 protein and mRNA levels in the blood, tumor tissue, and marginal normal tissue of patients with head and neck squamous cell carcinoma (HNSCC)usingthequantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC).
Materials and Methods:
This study was performed on 88 patients with HNSCC, who referred to the otorhinolaryngology and oral pathology departments, affiliated to Mashhad University of Medical Sciences, Mashhad, Iran, and a group of healthy subjects (i.e., control group) matched in terms of age and gender.RNA was collected from fresh tumor tissues, marginal tissues, and blood, followed by the implementation of quantitative PCR on the specimens.Furthermore, the expression of HMGB1 in tumor and normal margins was evaluated by means of IHC. Thedata were analyzed in SPSS software.
According to the results,the expression levels of HMGB1 protein and mRNA were significantly higher in the tumor tissue than in the normal margin tissues (P<0.01).In addition, there was a significant correlation between histologic grading and the expression of HMGB1 protein and mRNA in tissues (P<0.05). Furthermore, the receiver operating characteristic curve of the HMGB1 mRNA in tissue was located closer to the theoretical 100% sensitivity.
The findings revealed a higher increase in the levels of mRNA and HMGB1 protein in HNSCC, compared to those in the normal margin tissues. In addition, HMGB1 mRNA showed a significant expression in the tissue and blood of the patients with lymph node involvement.


Main Subjects

1. Arantes LMRB, De Carvalho AC, Melendez ME, Lopes Carvalho A. Serum, plasma and saliva biomarkers for head and neck cancer. Expert review of molecular diagnostics. 2018;18(1):85-112.

2. Stott-Miller M, Houck JR, Lohavanichbutr P, Méndez E, Upton MP, Futran ND, et al. Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma. Cancer Epidemiology and Prevention Biomarkers. 2011;20(12):2628-36.

3. Khademi B, Khademi B, Ghaderi A, Hosseini SF, Niknejad N. Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma. Iranian journal of otorhinolaryngology. 2013;25(72):161.

4. Atighechi S, Meybodian M, Dadgarnia MH, Baradaranfar MH, Behniafard N. Investigating the prevalence of human papilloma virus in squamous cell carcinoma of the larynx and its correlation with disease prognosis. Iranian journal of otorhinolaryngology. 2016;28(86):197.

5. Boscolo-Rizzo P, Zorzi M, Del Mistro A, Da Mosto MC, Tirelli G, Buzzoni C, et al. The evolution of the epidemiological landscape of head and neck cancer in Italy: Is there evidence for an increase in the incidence of potentially HPV-related carcinomas? PloS one. 2018; 13(2): e0192621.

6. Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, et al. HMGB1 in health and disease. Molecular aspects of medicine. 2014;40:1-116.

7. Thanos D, Maniatis T. The high mobility group protein HMG I (Y) is required for NF-κB-dependent virus induction of the human IFN-β gene. Cell. 1992;71(5):777-89.

8. Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, Trapasso F, et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Molecular and cellular biology. 2003;23(7):2225-38.

9. Fashena S, Reeves R, Ruddle N. A poly (dA-dT) upstream activating sequence binds high-mobility group I protein and contributes to lymphotoxin (tumor necrosis factor-beta) gene regulation. Molecular and cellular biology. 1992;12(2):894-903.

10. Thomas JO, Stott K. H1 and HMGB1: modulators of chromatin structure. Portland Press Limited; 2012.

11. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Molecular and cellular biology. 1999;19(8):5237-46.

12. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2010;1799(1):149-56.

13. Wild CA, Brandau S, Lotfi R, Mattheis S, Gu X, Lang S, et al. HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral oncology. 2012;48(5):409-16.

14. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annual review of immunology.2009;28: 367- 88.

15. Gokhale A, McLaughlin B, Flickinger J, Beriwal S, Heron D, Ferris R, et al. Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancers. Annals of oncology. 2009;21(1):145-51.

16. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: high mobility group box-1 and cancer. Clinical Cancer Research. 2007;13(10):2836-48.

17. Czura CJ, Wang H, Tracey KJ. Dual roles for HMGB1: DNA binding and cytokine. Journal of endotoxin research. 2001;7(4):315-21.

18. Cheng B-Q, Jia C-Q, Liu C-T, Lu X-F, Zhong N, Zhang Z-L, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Digestive and Liver Disease. 2008;40(6):446-52.

19. Lee H, Song M, Shin N, Shin CH, Min BS, Kim H-S, et al. Diagnostic significance of serum HMGB1 in colorectal carcinomas. PloS one. 2012;7(4):e34318.

20. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.Nature Reviews Immunology.2005;5(4):331.

21. Dong XDE, Ito N, Lotze MT, DeMarco RA, Popovic P, Shand SH, et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. Journal of immunotherapy. 2007;30(6):596-606.

22. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418 (6894): 191.

23. Tian J, Avalos AM, Mao S-Y, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nature immunology. 2007;8(5):487.

24. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248-51.

25. Müller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, et al. The double life of HMGB1 chromatin protein: architectural factor and extracellular signal. The EMBO journal. 2001; 20(16): 4337-40.

26. Kang R, Zhang Q, Zeh HJ, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clinical cancer research. 2013;19(15):4046-57.

27. Taguchi A, Blood DC, Del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405(6784):354.

28. Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature. 2014; 507(7490):109.

29. Mohtasham N, Babakoohi S, Montaser-Kouhsari L, Memar B, Salehinejad J, Rahpeyma A, et al. The expression of heat shock proteins 27 and 105 in squamous cell carcinoma of the tongue and relationship with clinicopathological index. Med Oral Patol Oral Cir Bucal. 2011;16(6):e730-5.

30. Hanakawa H, Orita Y, Sato Y, Takeuchi M, Takao S, Ohno K, et al. Does HMGB1 predict occult neck lymph node metastasis in early tongue carcinoma? A case–control study of 26 patients. The Journal of Laryngology & Otology. 2014; 128(10):926-31.

31. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a'DAMP'view of inflammatory arthritis. Nature Reviews Rheumatology. 2007;3(7):382.

32. Dahlmann M, Okhrimenko A, Marcinkowski P, Osterland M, Herrmann P, Smith J, et al. RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis. Oncotarget. 2014;5(10):3220.

33. Moser B, Janik S, Schiefer A-I, Müllauer L, Bekos C, Scharrer A, et al. Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology. PLoS One. 2014;9(4):e94118.

34. Zhang Q-Y, Wu L-Q, Zhang T, Han Y-F, Lin X. Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2. Oncology reports. 2015;33(4):1630-8.

35. Chung HW, Lee S-G, Kim H, Hong DJ, Chung JB, Stroncek D, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. Journal of translational medicine. 2009;7(1):38.

36. Sheng X, Du X, Zhang X, Li D, Lu C, Li Q, et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croatian medical journal. 2009;50(5):455-64.

37. Qian X, Coordes A, Kaufmann AM, Albers AE. Expression of aldehyde dehydrogenase family 1 member A1 and high mobility group box 1 in oropharyngeal squamous cell carcinoma in association with survival time. Oncology letters. 2016;12(5):3429-34.